In Vitro Antifungal Susceptibility of Malassezia pachydermatis Strains Isolated from Dogs with Chronic and Acute Otitis Externa
- 474 Downloads
Malassezia pachydermatis is a yeast that is frequently involved as a secondary/perpetuating factor in canine otitis externa. Topical therapies with different antifungal agents, mainly azole compounds, are generally successful in controlling the yeast overgrowth, but treatment failure and rapid recurrences are common. This study compared the in vitro antifungal susceptibility of M. pachydermatis isolates obtained from chronic and acute cases of otitis externa. The aim was to assess the possible onset of resistance mechanisms in isolates involved in long-lasting episodes with poor response to treatment. We evaluated the in vitro susceptibility to miconazole (MCZ) and clotrimazole (CTZ) of 42 isolates of M. pachydermatis obtained from dogs with chronic (group A, n = 25) and acute otitis (group B, n = 17), using a modified CLSI M27-A3 microdilution method. All isolates were inhibited by the antifungal agents employed, but Malassezia isolates from group A were significantly associated with higher minimum inhibitory concentration (MIC) values for both agents (Median MIC values: MCZ group A 2 µg/ml, group B 1 µg/ml; CTZ group A 8 µg/ml, group B 4 µg/ml). These findings prove that these isolates had a reduced in vitro susceptibility to the antifungal agents tested. However, it is unlikely that this could have any influence on the outcome of a topical treatment. Indeed, marketed products include concentrations of the tested agents that largely exceed even the highest MICs found in this study (in most cases at least 1,000 × the MIC, or greater). In conclusion, this study suggests that isolates of M. pachydermatis involved in chronic cases of canine external otitis and exposed to repeated antifungal treatments are unlikely to develop mechanisms of resistance of clinical relevance.
KeywordsMalassezia pachydermatis Antifungal susceptibility CLSI reference broth microdilution method Otitis externa
This work was supported by a grant of Elanco Animal Health, division of Eli Lilly Italy S.p.A. The authors express their acknowledgments to Elena Borio and Roberta Morandi for their laboratory support.
Conflict of interest
None to declare.
- 1.Miller WH, Griffin CE, Campbell K. Otitis externa. In: Muller and Kirk’s small animal dermatology. Philadelphia: WB Saunders; 2012.Google Scholar
- 3.Bond R, Guillot J, Cabanes J. Malassezia yeasts in animal diseases. In: Boekhout T, Guého-Kellermann E, Mayser P, Velegraki A, editors. Malassezia and the skin. Berlin: Springer; 2010. p. 271–99.Google Scholar
- 5.ESCCAP. Guideline 2 superficial mycoses in dogs and cats. 2011. http://www.esccap.org/uploads/docs/uh82a6e8_esccapgl2guidelines.pdf.
- 7.Coutinho SD, Paula CR. Susceptibility to antifungal agents of Malassezia pachydermatis isolates from dogs. Pol J Vet Sci. 2001;4:77–81.Google Scholar
- 8.Eichenberg M, Appelt CE, Berg V, Muschner A, Nobre M, Mata D, Alves S, Ferreiro L. Susceptibility of Malassezia pachydermatis to azole antifungal agents evaluated by a new broth microdilution method. Acta Sci Vet. 2003;31:75–80.Google Scholar
- 15.Hensel P, Austel M, Wooley RE, Keys D, Ritchie BW. In vitro and in vivo evaluation of a potentiated miconazole aural solution in chronic malassezia otitis externa in dogs. Vet Dermatol. 2009;20:429–434.Google Scholar
- 16.Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard, M27-A3. 3rd ed. Wayne, PA: NCCLS; 2008.Google Scholar
- 24.Nascente PDS, Mano Meinerz AR, de Faria RO, Dame Schuch LF, Araujo Meireles MC, Bragade Mello JR. Comparison of the broth microdilution technique and ETEST to ketoconazole front Malassezia pachydermatis. Braz J Vet Res Anim Sci. 2009;40:222–6.Google Scholar
- 30.Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry AL. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro–in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis. 1997;24:235–47.PubMedCrossRefGoogle Scholar